

AUG. 23, 2010 11:10AM

OBLOM SPIVAK

NO. 221 P. 2

RECEIVED
CENTRAL FAX CENTER

Docket No: 279089us

AUG 23 2010

Applicant Initiated Interview Request FormApplication No.: 10/551,929 First Named Applicant: Frederic TaranExaminer: HAQ, SHAFIQUL Art Unit: 1641 Status of Application: Pending**Tentative Participants:**(1) Soonwuk Cheong (2) HAQ, SHAFIQUL

(3) _____ (4) _____

Proposed Date of Interview: August 23, 2010 Proposed Time: 11 AM(1) Telephonic (2) Personal (3) Video ConferenceExhibit To Be Shown or Demonstrated: [] YES NO

If yes, provide brief description: _____

Issues To Be Discussed

Issues (Rej., Obj., etc)	Claims/Fig. #s	Prior Art	Discussed	Agreed	Not Agreed
(1) 112	<u>27-29, 31-35, 37, 38, 40, 42-45 and 48-53</u>	_____	[]	[]	[]
(2) _____	_____	_____	[]	[]	[]
(3) _____	_____	_____	[]	[]	[]
(4) _____	_____	_____	[]	[]	[]

[] Continuation Sheet Attached

Brief Description of Arguments to be Presented:Applicants would like to discuss what claims scope would be commensurate in scope with the disclosure of the specification.

An interview was conducted on the above-identified application on _____.

NOTE:

This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).

This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.

(Applicant/Applicant's Representative Signature)

(Examiner/SPE Signature)

Proposed Claim 27: A method of screening operating conditions of a coupling reaction of at least two functional groups, comprising:

i) reacting together at least two compounds:

a first compound of formula $E_1-X_1-G_1$ in which G_1 represents a first of said at least two functional groups, X_1 represents a covalent bond or a first spacer group, and E_1 represents the residue of a first molecule M_1 for which a first specific antibody AC_1 is available; and

a second compound of formula $E_2-X_2-G_2$ in which G_2 represents a second of said at least two functional groups, X_2 represents a covalent bond or a second spacer group, which is optionally identical to or different from X_1 , and E_2 represents either a residue of a second molecule M_2 that is different from M_1 and for which a second specific antibody AC_2 is available, or a group capable of forming at least one covalent bond with the antibody AC_1 in the presence of a coupling agent,

wherein said at least two compounds are reacted in a solution comprising a solvent under predetermined operating conditions comprising a candidate operating condition to obtain a reaction medium and in the reaction medium, to obtain a compound Z composed of comprising the chain $E_1-X_1-G_1-G_2-X_2-E_2$ comprising the E_1 , X_1 , E_2 , X_2 and E_2 , wherein G_1-G_2 represents the group of atoms resulting from the coupling of said at least two functional groups;

ii) determining the concentration of the obtained compound Z in the reaction medium at a predetermined reaction time t , by at least one immunoassay, said immunoassay comprising at least:

bringing the reaction medium obtained at reaction time t into contact with a solid phase on which the first antibody AC_1 is immobilized so as to obtain the attachment of the compound Z to said solid phase by immunobinding between the antibody AC_1 and the residue E_1 of the compound Z ;

removing the reaction medium;

measuring the amount of compound Z attached to the solid phase; and

determining, on a standard range, the concentration of the obtained compound Z in the reaction medium at said time t , from the amount of compound Z thus measured;

comprising at least the antibody AC_1 ; and

iii) evaluating the effects of the candidate operating condition(s) on said coupling reaction by the concentration of compound Z thus determined.